TUBB binds colchicine

Colchicine is an antimitotic agent used to treat gout and Behçet's disease (Cerquaglia et al. 2005, Saleh & Arayssi 2014, Angelidis et al. 2018). It works by decreasing inflammation. Colchicine primarily inhibits tubulin (TUBB) (Lu et al. 2012), preventing microtubule polymerization and thereby disrupts inflammasome activation, microtubule-based inflammatory cell chemotaxis, generation of leukotrienes and cytokines, and phagocytosis.<br><br>The COLCORONA trial conducted by the Montreal Heart Institute (MHI) (https://clinicaltrials.gov/ct2/show/NCT04322682) showed that the use of colchicine was associated with statistically significant reductions in the risk of death or hospitalization in patients with Covid-19 compared to placebo. Colchinine showed efficacy in preventing the 'cytokine storm' and other complications associated with Covid-19.

秋水仙碱作为一种抗有丝分裂药物，被广泛应用于治疗痛风及贝赫切特病（Cerquaglia 等人，2005年；Saleh 与 Arayssi，2014年；Angelidis 等人，2018年）。其作用机制在于降低炎症反应。秋水仙碱主要通过抑制微管蛋白（TUBB）（Lu 等人，2012年），阻止微管的聚合，从而干扰炎症小体的激活、基于微管的炎症细胞趋化作用、白三烯和细胞因子的生成，以及吞噬作用。《COLCORONA》临床试验由蒙特利尔心脏研究所（MHI）进行（https://clinicaltrials.gov/ct2/show/NCT04322682），结果显示，与安慰剂相比，秋水仙碱的使用与COVID-19患者死亡或住院风险的显著降低相关。秋水仙碱在预防“细胞因子风暴”及其他与COVID-19相关的并发症方面展现出其有效性。